Lyka Labs Ltd

Lyka Labs Ltd

$LYKALABSPharmaceuticalsNSEBSE

Lyka Labs Ltd (LYKALABS) last traded at ₹76.4, a market capitalisation of ₹276 crore. Over the past 52 weeks the stock has ranged between ₹44.1 and ₹105. Lyka Labs Ltd last reported results for the quarter ended Jun 2026, with sales of ₹42.31 crore and net profit of ₹2.05 crore. Figures are as of 25 Aug 2026 and are not real time.

Lyka Labs Ltd share price and key metrics

Current price
₹76.4
Market cap
₹276 cr
Book value
₹25.9
ROE
-10.2%
ROCE
-5.98%
Dividend yield
0.00%
52w high / low
105/44.1

Metrics as of 25 Aug 2026. Not real time.

Lyka Labs Ltd quarterly results

In the quarter ended Jun 2026, sales were ₹42.31 cr, up 28.1% from ₹33.03 cr a year earlier. Net profit was ₹2.05 cr, up 107.1% year on year.

Lyka Labs Ltd consolidated quarterly results, figures in ₹ crore
₹ croreSep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales41.1633.833.4333.0336.6630.7328.0342.31
Expenses36.2128.6129.3529.3539.229.0834.4837.76
Operating profit4.955.194.083.68-2.541.65-6.454.55
OPM %12.03%15.36%12.20%11.14%-6.93%5.37%-23.01%10.75%
Other income0.030.830.820.631.091.160.610.42
Interest0.540.610.470.850.790.820.71.01
Depreciation1.761.831.422.112.152.152.042.01
Profit before tax2.683.583.011.35-4.39-0.16-8.581.95
Tax %28.36%24.30%32.89%26.67%-26.65%-6.25%-6.06%-5.13%
Net profit1.912.72.030.99-3.22-0.15-8.072.05
EPS (₹)0.590.760.500.26-0.940.00-2.130.57

Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.

Lyka Labs Ltd annual results

Lyka Labs Ltd annual profit and loss, figures in ₹ crore
₹ croreMar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales8619493111138128138
Operating profit20101171618-3-3
OPM %23%52%18%14%13%-2.7%-2.0%
Net profit-1038-13-38-10-9
EPS (₹)-4.0313.59-4.30-0.752.24-2.81-2.50

TTM is the trailing twelve months to the most recent quarter.

Lyka Labs Ltd growth and returns

Compounded Sales Growth
10 Years
0%
5 Years
8%
3 Years
11%
TTM
-3%
Compounded Profit Growth
10 Years
%
5 Years
1%
3 Years
-32%
TTM
-219%
Stock Price CAGR
10 Years
1%
5 Years
0%
3 Years
-15%
1 Year
-25%
Return on Equity
10 Years
%
5 Years
%
3 Years
-2%
Last Year
-10%

Lyka Labs Ltd shareholding pattern

Promoters held 58.45% at Jun 2026, broadly unchanged since Jun 2025. FIIs 0.17% and DIIs 0.66%.

Lyka Labs Ltd shareholding pattern by quarter, in percent
% heldSep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters58.11%58.11%58.16%58.16%58.16%58.16%58.16%58.45%
FIIs0.15%0.15%0.24%0.16%0.17%0.17%0.29%0.17%
DIIs0.66%0.66%0.66%0.66%0.66%0.66%0.66%0.66%
Public41.08%41.07%40.93%41.02%40.99%40.99%40.89%40.73%
No. of shareholders28,94329,09928,47228,18927,74327,15526,72729,369

As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.

Lyka Labs Ltd corporate filings

  • Announcement under Regulation 30 (LODR)-Newspaper PublicationCompany Updatelow impact
    Filing PDF

    Cruxal's analysis: Lyka Labs Ltd has fulfilled its regulatory obligation under Regulation 30 of the SEBI…

    Read the full analysis
  • Shareholder Meeting / Postal Ballot-Scrutinizer''s ReportAGM/EGMlow impact
    Filing PDF

    Cruxal's analysis: Lyka Labs Limited has successfully concluded its 47th Annual General Meeting held on 10th…

    Read the full analysis
  • Revised Press Release On Unaudited Financial Results For The Q1 June, 2026Company Updatehigh impact
    Filing PDF

    Cruxal's analysis: Lyka Labs Limited has released its unaudited financial results for the quarter ended June…

    Read the full analysis
  • Shareholder Meeting / Postal Ballot-Outcome of AGMAGM/EGMlow impact
    Filing PDF

    Cruxal's analysis: Lyka Labs Limited has successfully concluded its 47th Annual General Meeting held on 10th…

    Read the full analysis
  • Press Release For Unaudited Financial Results Of Q1 June 2026Company Updatehigh impact
    Filing PDF

    Cruxal's analysis: Lyka Labs Limited has announced robust financial results for Q1 FY27, with consolidated…

    Read the full analysis
  • Board Meeting Outcome for Outcome Of The Board Meeting Dated 10Th August, 2026Board Meetinghigh impact
    Filing PDF

    Cruxal's analysis: Lyka Labs Limited reported a turnaround in Q1 FY2027 with a standalone net profit of 2.10…

    Read the full analysis

This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.

Track Lyka Labs Ltd

Cruxal reads every Lyka Labs Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.

Cruxal publishes market data and coverage for information only. Nothing here is investment advice.

Lyka Labs Ltd (LYKALABS) Results, Financials & Share Price | Cruxal